Journal article icon

Journal article

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

Abstract:

BACKGROUND: Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. The aim of this study was to assess prospectively the drug's ability to prevent type 2 diabetes in individuals at high risk of developing the condition. METHODS: 5269 adults aged 30 years or more with impaired fasting glucose or impaired glucose tolerance, or both, and no previous cardiovascular disease were recruited from 191 sites in 21 countries and randomly assigned to r...

Expand abstract

Actions


Access Document


Authors


Journal:
Lancet More from this journal
Volume:
368
Issue:
9541
Pages:
1096-1105
Publication date:
2006-09-01
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
Language:
English
Keywords:
Pubs id:
pubs:9805
UUID:
uuid:cd2e1eac-c698-4bec-915b-af6f73be9a05
Local pid:
pubs:9805
Source identifiers:
9805
Deposit date:
2012-12-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP